JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Waltz, T. L.
Right arrow Articles by Pollack, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waltz, T. L.
Right arrow Articles by Pollack, H.
Journal of Clinical Microbiology, January 2005, p. 254-258, Vol. 43, No. 1
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.1.254-258.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Development of a Molecular-Beacon Assay To Detect the G1896A Precore Mutation in Hepatitis B Virus-Infected Individuals

Therese L. Waltz,1 Salvatore Marras,2 Gemma Rochford,1 John Nolan,1 Eugenia Lee,1 Margherita Melegari,3 and Henry Pollack1*

Division of Pediatric Infectious Diseases,1 Department of Microbiology, New York University School of Medicine, New York, New York,3 Public Health Research Institute, Newark, New Jersey2

Received 2 June 2004/ Returned for modification 18 July 2004/ Accepted 18 September 2004

The 1896 precore (PC) mutation is the most frequent cause of hepatitis B virus e-antigen (HBeAg)-negative chronic hepatitis B virus (HBV) infection. Detection of the 1896 PC mutation has application in studies monitoring antiviral therapy and the natural history of the disease. Identification of this mutation is usually performed by direct sequencing, which is both costly and laborious. The aim of this study was to develop a rapid, high-throughput assay to detect the 1896 PC mutation using real-time PCR and molecular-beacon technology. The assay was initially standardized on oligonucleotide targets and plasmids containing the wild-type (WT) and PC mutation and then tested on plasma samples from children with HBV DNA of >106 copies/ml. Nine individuals were HBeAg negative and suspected to harbor HBeAg mutations, while 12 children were HBeAg positive and selected as controls. Ninety percent (19 of 21) of plasma samples tested with molecular beacons were in complete agreement with sequencing results. The remaining 10% (2 of 21) of samples were identified as heterogeneous mixtures of WT and mutant virus by molecular beacons, though sequencing found only a homogeneous mutant in both cases. Overall, the 1896 PC mutation was detected by this assay in 55.5% of the children with HBeAg-negative infection. In summary, this assay is a rapid, sensitive, and specific technique that effectively discriminates WT from 1896 PC mutant HBV and may be useful in clinical and epidemiological studies.


* Corresponding author. Mailing address: Division of Pediatric Infectious Diseases, 550 First Ave., New York, NY 10016. Phone: (212) 263-8197. Fax: (212) 263-7806. E-mail: Henry.Pollack{at}med.nyu.edu.


Journal of Clinical Microbiology, January 2005, p. 254-258, Vol. 43, No. 1
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.1.254-258.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2005 by the American Society for Microbiology. All rights reserved.